D. E. Shaw & Co. Inc. Lowers Stake in Azenta, Inc. (NASDAQ:AZTA)

D. E. Shaw & Co. Inc. cut its position in Azenta, Inc. (NASDAQ:AZTA - Free Report) by 35.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 300,784 shares of the company's stock after selling 165,014 shares during the period. D. E. Shaw & Co. Inc. owned about 0.66% of Azenta worth $15,039,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Ballentine Partners LLC lifted its stake in shares of Azenta by 2.0% during the 4th quarter. Ballentine Partners LLC now owns 20,340 shares of the company's stock valued at $1,017,000 after buying an additional 404 shares in the last quarter. Boothbay Fund Management LLC raised its holdings in Azenta by 8.4% during the fourth quarter. Boothbay Fund Management LLC now owns 6,571 shares of the company's stock valued at $329,000 after acquiring an additional 509 shares during the period. Picton Mahoney Asset Management lifted its position in shares of Azenta by 305.7% in the fourth quarter. Picton Mahoney Asset Management now owns 706 shares of the company's stock valued at $35,000 after acquiring an additional 532 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of Azenta by 14.9% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,446 shares of the company's stock worth $225,000 after acquiring an additional 576 shares during the period. Finally, KBC Group NV grew its position in shares of Azenta by 48.5% during the fourth quarter. KBC Group NV now owns 2,137 shares of the company's stock worth $107,000 after purchasing an additional 698 shares in the last quarter. 99.08% of the stock is owned by hedge funds and other institutional investors.

Azenta Trading Up 5.7%

Shares of Azenta stock opened at $28.30 on Tuesday. The firm has a market cap of $1.29 billion, a PE ratio of -9.50 and a beta of 1.64. The stock has a 50 day moving average of $31.20 and a 200 day moving average of $41.95. Azenta, Inc. has a 12 month low of $23.91 and a 12 month high of $63.58.

Azenta (NASDAQ:AZTA - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.05 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.04). Azenta had a negative net margin of 24.91% and a positive return on equity of 1.25%. During the same period in the prior year, the company earned $0.06 EPS. The company's quarterly revenue was up 5.1% on a year-over-year basis. As a group, equities research analysts forecast that Azenta, Inc. will post 0.53 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on AZTA shares. Evercore ISI boosted their price target on Azenta from $50.00 to $52.00 and gave the stock an "in-line" rating in a report on Thursday, February 6th. Needham & Company LLC dropped their target price on shares of Azenta from $59.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, TD Cowen raised shares of Azenta to a "hold" rating in a research note on Thursday, February 27th.

About Azenta

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.

Want to see what other hedge funds are holding AZTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Azenta, Inc. (NASDAQ:AZTA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.